,
6 min read
Building a regulated software is not just a product challenge, it is an operating model challenge. For startups and MSMEs (Micro, Small, and Medium Enterprises) developing medical software, the hardest part is not only writing a procedure; it is designing a system that keeps pace with rapid iteration while still providing the traceability, evidence, and control that regulators expect.
A scalable SaMD QMS must do two things at once, i.e., protect patients through disciplined lifecycle controls, and protect innovators from bureaucracy that slows learning. The objective is not to copy a legacy MedTech binder-based system, but to build a QMS that is lean, auditable, and compatible with modern software delivery.
A clear QMS architecture is what separates scalable compliance from administrative burden. When the system is designed around risk, change control, and evidence, rather than documentation volume, it supports both speed and quality. In practice, this architecture is most anchored in Medical Device Quality Management System (ISO 13485) for organization-wide controls and Medical Software Lifecycle Management (IEC 62304) compliance.
The Core Framework: ISO 13485 + IEC 62304, Designed for Scale
A scalable ISO 13485 QMS begins with strong organizational fundamentals, document control, training, supplier oversight, CAPA, internal audits, and management review. Still, it only becomes truly effective when those controls are tightly connected to day-to-day engineering practices. Rather than treating the standard as a checklist, high-performing teams use it as a governance framework that reinforces consistency, traceability, and sustained Regulatory readiness. Referencing the official ISO 13485 quality management system description directly within your QMS rationale can help teams interpret expectations with clarity.
On the software side, IEC 62304 compliance provides the lifecycle structure, planning, requirements, architecture, implementation, verification, release, maintenance, and problem resolution. In practice, IEC 62304 becomes the bridge between your software workflow and your audit-ready evidence. When teams need a single “source of truth” for lifecycle expectations, the publication reference for IEC 62304 is helpful to ground interpretation.
For startups, the goal is integration: ISO 13485 provides the system-wide quality scaffolding, while IEC 62304 anchors the software engine that runs inside it. This combined approach is the backbone of QMS for SaMD in real-world operating models.
A Practical QMS Implementation Plan for MSMEs and Startups
A scalable QMS implementation plan is best executed in phases, aligned to product maturity and risk, not company ambition. You do not need “enterprise QMS” on day one; you need the right controls at the right time.
Phase 1: Establish the minimum viable system
Focus on the essentials for controlled development: document control, training, design controls aligned to your lifecycle, risk management integration, basic supplier controls, and a change management process that is simple enough to use.
Phase 2: Build audit-ready traceability.
As you approach clinical validation and submission readiness, strengthen traceability from requirements to risks to tests and outcomes. This is where QMS design should reflect the realities of agile software delivery, i.e., smaller increments, frequent releases, and validated change impacts.
Phase 3: Scale into lifecycle governance.
Once products are in the field, your QMS must manage sustained vigilance. PMS inputs, cybersecurity patch management, complaint handling, CAPA, and periodic reviews that demonstrate ongoing control.
This staged approach keeps QMS for medical devices practical while preserving the discipline required for Regulatory confidence.
SOP Writing That Works: From “Documents” to “Decision Systems”
For many MSMEs, SOPs fail because they are written to satisfy audits rather than to shape behaviour. Good SOPs make decisions predictable. They define who decides, what evidence is needed, what thresholds matter, and how the output is recorded.
A strong SOP set for SaMD typically focuses on a few “high leverage” areas:
- Software lifecycle management (aligned to IEC 62304): Planning, requirements, verification/validation, release, and maintenance.
- Risk and usability integration: How hazards are identified, controlled, assessed, and updated through change
- Change control and impact assessment: What triggers revalidation and what counts as a significant change.
- Cybersecurity vulnerability handling: Intake → triage → patch → verification → communication
- Supplier and open-source controls: How components are evaluated, approved, monitored, and updated
Keep SOPs short, enforceable, and written in operational language. A useful benchmark is that a new engineer should be able to follow the SOP, and a regulator should be able to audit it. If it fails either test, simplify.
Align QMS to Regulatory Expectations Without Overbuilding
Startups often ask, “How much QMS is enough?” The ideal answer is that it should be enough to show control over what matters, i.e., safety, performance, and change.
In the US context, regulators evaluate whether you have effective design controls, validation discipline, and robust quality processes; the FDA’s quality system and design control expectations provide important context for how a compliant system is interpreted in practice.
In the European Union, expectations are shaped by the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), with oversight by Notified Bodies; regulators assess conformity with Annex I General Safety and Performance Requirements, risk management (aligned with ISO 14971), clinical evaluation, post-market surveillance, and the effectiveness of the manufacturer’s quality management system (typically aligned with ISO 13485).
In the rest of the world (ROW), Regulatory frameworks vary but often align with principles from the International Medical Device Regulators Forum (IMDRF), ISO 13485, and risk-based classification systems. Authorities such as Health Canada, TGA (Australia), PMDA (Japan), and others evaluate the maturity of design controls, validation rigor, supplier management, and post-market processes, frequently leveraging prior approvals or certifications (e.g., CE marking, MDSAP) as part of their review.
The strategic principle is risk-based proportionality. The higher the risk and clinical impact, the higher the expected rigor. But even for lower-risk products, lack of basic control (unclear requirements, inconsistent testing, uncontrolled changes) is a common root cause of Regulatory friction.
Making It Scalable: The “Modern QMS” Mindset
The most scalable SaMD QMS designs share a few characteristics:
- Process is embedded in tools (e.g., change control integrated with issue tracking, validation evidence tied to CI/CD artifacts).
- Traceability is automated where possible, reducing human error and manual compilation.
- Governance is lightweight but consistent, so the same logic is applied across releases and records.
This is how companies avoid “QMS as overhead” and build “QMS as an operating system.”
Closing perspective
A well-constructed SaMD QMS is an investment in trust that the software behaves as intended, trust that risk is managed systematically, and trust that change is governed with discipline. When ISO 13485 QMS controls are designed to match software realities, and IEC 62304 compliance is treated as a practical lifecycle blueprint, startups can scale quality without scaling bureaucracy.
In practice, teams that treat QMS as a lifecycle discipline by linking evidence durability, risk controls, and change governance tend to align more consistently with the expectations outlined in the Comprehensive Guide to Software as a Medical Device (SaMD) Compliance & Global Registration.
Contact Freyr Solutions to discuss your SaMD Regulatory strategy and discover how Freyr can streamline your global registrations.
